Blood test could spot Immunotherapy-Linked liver damage
NCT ID NCT06470997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improve diagnosis and treatment of this side effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors quickly identify and treat hepatitis caused by immunotherapy, avoiding unnecessary treatments.
- What could go wrong
- This is a small, early-stage study focused on finding markers, not testing a treatment. The markers may not prove reliable in larger, more diverse groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Montpellier
RECRUITINGMontpellier, France, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Could a common drug stop a rare liver disease from returning after transplant?